Skip to main content
SpringerLink
Log in

From first to second generation antipsychotics

  • Chapter
Atypical Antipsychotics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

As late as 1993, 85% of psychotic inpatients at a major university psychiatric referral centre in the United States were found to be receiving antipsychotic drugs that had been available for some three decades or more, most commonly perphenazine and haloperidol, with an additional 2% receiving loxapine and 13% receiving clozapine [1]. Since the identification in the 1950s of chlorpromazine as the archetype antipsychotic, a profound advance that has received personal, historical documentation by one of the principal innovators [2], their properties have been subject to extensive contemporary review [3–7]. Yet these reviews share at least one chastening theme: enduring uncertainty, in the face of extensive clinical use over four decades, as to a number of quite fundamental aspects of their antipsychotic actions, including such basic issues as diagnostic specificity, time-course of therapeutic effect, optimal dosage and most effective treatment strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini RJ, Kando JC, Centorrino F (1995) Hospital use of antipsychotic agents in 1989 and 1993.Am JPsychiat152: 1038–1044

    CAS  Google Scholar 

  2. Deniker P (1983) Discovery of the clinical use of neuroleptics. In: MJ Parnham, J Bruinvels (eds):Discoveries in pharmacologyVol 1:Psycho-and Neuropharmacology.Elsevier, Amsterdam, 163–180

    Google Scholar 

  3. Ellenbroek BA (1993) Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.Pharmacol Ther 57:1–78

    Article  PubMed  CAS  Google Scholar 

  4. Johnstone EC (1993) Schizophrenia: problems in clinical practice. Lancet 341: 536–538

    Article  PubMed  CAS  Google Scholar 

  5. Dixon LB, Lehman AF, Levine J (1995) Conventional antipsychotic medications for schizophrenia.Schizophr Bull21: 567–577

    Article  PubMed  CAS  Google Scholar 

  6. Waddington JL (1995) The clinical psychopharmacology of antipsychotic drugs in schizophrenia. In: SR Hirsch, DR Weinberger (eds):Schizophrenia.Blackwell, Oxford, 341–357

    Google Scholar 

  7. Kane JM (1996) Drug therapy: Schizophrenia.NEngl JMed334: 34–41

    Article  CAS  Google Scholar 

  8. Johnstone EC, Crow TJ, Frith CD, Owens DGC (1988) The Northwick Park “functional” psychosis study: diagnosis and treatment response.Lancetii: 119–125

    Article  Google Scholar 

  9. Keck PE, Cohen BM, Baldessarini RJ, McElroy SL (1989) Time course of antipsychotic effects of neuroleptic drugs.Am JPsychiat146: 1289–1292

    Google Scholar 

  10. Glovinsky D, Kirch DG, Wyatt RJ (1992) Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients.Biol Psychiat31: 968–970

    Article  PubMed  CAS  Google Scholar 

  11. Mazure CM, Nelson JC, Jatlow PI, Bowers MB (1992) Drug-response symptoms during early neuroleptic treatment.Psychiat Res41: 147–154

    Article  CAS  Google Scholar 

  12. Stern RG, Kahn RS, Harvey PD, Amin F, Apter SH, Hirschowitz J (1993) Early response to haloperidol treatment in chronic schizophrenia.Schiz Res 10:165–171

    Article  CAS  Google Scholar 

  13. Nordstrom AL, Farde L, Halldin C (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol.Psychopharmacology106: 433–438

    Article  PubMed  CAS  Google Scholar 

  14. Baldessarini RJ, Cohen B, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.Arch Gen Psychiat45: 79–91

    Article  PubMed  CAS  Google Scholar 

  15. Van Putten T, Marder SR, Mintz J (1990) A controlled dose comparison of haloperidol in newly admitted schizophrenic patients.Arch Gen Psychiat47: 754–578

    Article  PubMed  Google Scholar 

  16. Rifkin A, Doddi S, Karajgi B, Borenstein M, Wachspress M (1991) Dosage of haloperidol for schizophrenia.Arch Gen Psychiat48: 166–170

    Article  PubMed  CAS  Google Scholar 

  17. McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia.Arch Gen Psychiat48: 739–745

    Article  PubMed  CAS  Google Scholar 

  18. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J (1995) Further evidence of a dose-response threshold for haloperidol in psychosis.Am JPsychiat152: 1210–1212

    CAS  Google Scholar 

  19. Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos MJ, Silver P (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.Arch Gen Psychiat47: 761–768

    Article  PubMed  CAS  Google Scholar 

  20. Van Putten T, Marder SR, Mintz J, Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship.Am JPsychiat149: 500–505

    Google Scholar 

  21. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, Gastanaga P, Krakowski M, Chou J, Crowner M, Douyon R (1992) Haloperidol blood levels and clinical effects.Arch Gen Psychiat49: 354–361

    Article  PubMed  CAS  Google Scholar 

  22. Volavka J, Cooper TB, Czobor P, Meisner M (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.Arch Gen Psychiat52: 837–845

    Article  PubMed  CAS  Google Scholar 

  23. Coryell W, Miller DD, Perry PJ (1998) Haloperidol plasma levels and dose optimization.Am JPsychiat155: 48–53

    CAS  Google Scholar 

  24. Marder SR, Hubbard JW, Van Putten T, Midha KK (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.Psychopharmacology98: 433–439

    Article  PubMed  CAS  Google Scholar 

  25. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D, and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine.Arch Gen Psychiat49: 538–544

    Article  PubMed  CAS  Google Scholar 

  26. Wolkin A, Brodie JD, Barouche F, Rotrosen J, Wolf AP, Smith M, Fowler J, Cooper TB (1989) Dopamine receptor occupancy and plasma haloperidol levels.Arch Gen Psychiat46: 482–483

    Article  PubMed  CAS  Google Scholar 

  27. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L (1995) D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.Am JPsychiat152: 173–178

    CAS  Google Scholar 

  28. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.Am JPsychiat153: 948–950

    CAS  Google Scholar 

  29. Nyberg S, Farde L, Halldin C (1997) Delayed normalization of central D2dopamine receptor availability after discontinuation of haloperidol decanoate.Arch Gen Psychiat54: 953–958

    Article  PubMed  CAS  Google Scholar 

  30. Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S (1997) The relationship between D2receptor occupancy and plasma levels on low dose oral haloperidol: a PET study.Psychopharmacology131: 148–152

    Article  PubMed  CAS  Google Scholar 

  31. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan BW (1990) Continuous vs. targeted medications in schizophrenic outpatients: outcome results.Am JPsychiat147: 1138–1148

    Google Scholar 

  32. Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.Br Med J301:837–842

    Article  CAS  Google Scholar 

  33. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A et al (1997) Relapse and rehospitalization during maintenance treatment of schizophrenia.Arch Gen Psychiat54: 453–463

    Article  PubMed  CAS  Google Scholar 

  34. Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients.Arch Gen Psychiat52: 173–188

    Article  PubMed  CAS  Google Scholar 

  35. Viguera AC, Baldessarini RJ, Hegarty MD, van Kammen DP, Tohen M (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment.Arch Gen Psychiat54: 49–55

    Article  PubMed  CAS  Google Scholar 

  36. Moller HJ, van Praag HM, Aufdembrinke B, Bailey P, Barnes TRE, Beck J, Bentsen H, Eich FX, Farrow L, Fleishhacker WW et al (1994) Negative symptoms in schizophrenia: considerations for clinical trials.Psychopharmacology115: 221–228

    Article  PubMed  CAS  Google Scholar 

  37. King DJ (1998) Drug treatment of the negative symptoms of schizophrenia.Eur Neuropsychopharmacol8: 33–42

    Article  PubMed  CAS  Google Scholar 

  38. Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia.Am J Psychiat151: 825–835

    PubMed  CAS  Google Scholar 

  39. Hamilton SH, Revicki DA, Genduso LA, Beasley CM (1998) Olanzapine vs. placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.Neuropsychopharmacol18: 41–49

    Article  CAS  Google Scholar 

  40. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB and the Sertindole Study Group (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia.Am JPsychiat154: 782–791

    CAS  Google Scholar 

  41. Arvanitis LA, Miller BG and the Seroquel Trial 13 Study Group (1997) Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo.Biol Psychiat42: 233–246

    Article  PubMed  CAS  Google Scholar 

  42. Kirkpatrick B, Carpenter WT (1995) Drug development and the deficit syndrome of schizophrenia.Biol Psychiat38: 277–278

    Article  PubMed  CAS  Google Scholar 

  43. Moller HJ, Muller H (1997) Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms.Eur Arch Psychiat Clin Neurosci247: 1–5

    Article  CAS  Google Scholar 

  44. Tollefson GD, Sanger TM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine.Am JPsychiat154: 466–474

    CAS  Google Scholar 

  45. Volavka J, Cooper TB, Czobor P, Meisner M (1996) Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.Psychopharmacol Bull32: 75–79

    PubMed  CAS  Google Scholar 

  46. Voruganti L, Heslegrave R, Awad AG, Seeman MV (1998) Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability.Psychol Med28: 165–172

    Article  PubMed  CAS  Google Scholar 

  47. Lehman AF (1996) Evaluating outcomes of treatments for persons with psychotic disorders.JClin Psychiat57 (Suppl 11): 61–67

    Google Scholar 

  48. Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen AM, Weiden P (1993) Treatment of neuroleptic-resistant schizophrenic relapse.Psychopharmacol Bull29: 309–314

    Google Scholar 

  49. Conley RR, Buchanan RW (1997) Evaluation of treatment-resistant schizophrenia.Schizophr Bull23: 663–674

    Article  PubMed  CAS  Google Scholar 

  50. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.Am JPsychiat146: 905–908

    CAS  Google Scholar 

  51. Coppens HJ, Slooff CJ, Paans AMJ, Wiegman T, Vaalburg W, Korf J (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.Biol Psychiat29: 629–634

    Article  PubMed  CAS  Google Scholar 

  52. Liberman RP, Van Putten T, Marshall BD, Mintz J, Bowen L, Kuehnel TG, Aravagiri M, Marder SR (1994) Optimal drug and behaviour therapy for treatment-refractory schizophrenic patients.Am JPsychiat151: 756–759

    CAS  Google Scholar 

  53. Barnes TRE, McPhillips MA (1996) Antipsychotic-induced extrapyramidal symptoms: role of anticholinergic drugs in treatment.CNS Drugs6: 315–330

    Article  CAS  Google Scholar 

  54. Hansen TE, Casey DE, Hoffman WF (1997) Neuroleptic intolerance.Schizophr Bull23: 567–582

    Article  PubMed  CAS  Google Scholar 

  55. Waddington JL (1992) Mechanisms of neuroleptic-induced extrapyramidal side effects. In: JM Kane, JA Lieberman (eds):Adverse effects of psychotropic drugs.Guilford Press, New York, 246–265

    Google Scholar 

  56. Meltzer HY (1995) Atypical antipsychotic drug therapy for treatment-resistant schizophrenia. In: SR Hirsch, DR Weinberger (eds):SchizophreniaBlackwell, Oxford, 485–502

    Google Scholar 

  57. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL (1998) Binding of antipsychotic drugs to cortical 5-HT2Areceptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.Am J Psychiat 155:505–508

    PubMed  CAS  Google Scholar 

  58. Kapur SJ, Zipursky R, Remington G, Jones C, McKay G, Houle S (1997) PET evidence that loxapine is an equipotent blocker of 5-HT2and D2 receptors: implications for the therapeutics of schizophrenia.Am JPsychiat154: 1525–1529

    CAS  Google Scholar 

  59. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA (1992) Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull 28: 353–366

    CAS  Google Scholar 

  60. Green JF, King DJ (1996) Cognitive functioning in schizophrenia: effects of drug treatment.CNS Drugs6: 382–398

    Article  CAS  Google Scholar 

  61. Mortimer AM (1997) Cognitive function in schizophrenia — do neuroleptics make a difference?Pharmacol Biochem Behav56: 789–795

    Article  PubMed  CAS  Google Scholar 

  62. Waddington JL, O’Callaghan E (1997) What makes an antipsychotic “atypical”? Conserving the definition.CNS Drugs7: 341–346

    Article  CAS  Google Scholar 

  63. Ackerman S, Nolan LJ (1998) Bodyweight gain induced by psychotropic drugs.CNS Drugs9: 135--151

    Article  CAS  Google Scholar 

  64. Jusic N, Lader M (1994) Post-mortem antipsychotic drug concentrations and unexplained deaths.BrJPsychiat165: 787–791

    CAS  Google Scholar 

  65. Warner JP, Barnes TRE, Henry JA (1996) Electrocardiographic changes in patients receiving neuroleptic medication.Acta Psychiat Scand93: 311–313

    Article  PubMed  CAS  Google Scholar 

  66. Working Group of the Royal College of Psychiatrists, Psychopharmacology Sub-Group (1997) The association between antipsychotic drugs and sudden death.Council Report CR57Royal College of Psychiatrists, London

    Google Scholar 

  67. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type.Br Med J305:673–678

    Article  CAS  Google Scholar 

  68. Joseph KS, Blais L, Ernst P, Suissa S (1996) Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers.Br Med J312:79–83

    Article  CAS  Google Scholar 

  69. Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjuctive anticholinergics over the course of a 10-year prospective study.BrJPsychiat173: 325–329

    CAS  Google Scholar 

  70. Kane JM (1995) Psychopharmacological approaches to schizophrenia: practical aspects. In: JA Den Boer, HGM Westenberg, HM Van Praag (eds):Advances in the neurobiology of schizophrenia.Wiley, Chichester, 245–263

    Google Scholar 

  71. Day JC, Kinderman P, Bentall R (1998) A comparison of patients’ and prescribers’ beliefs about neuroleptic side-effects: prevalence, distress and causation.Acta Psychiat Scand97: 93–97

    Article  PubMed  CAS  Google Scholar 

  72. Awad AG (1993) Subjective response to neuroleptics in schizophrenia.Schizophr Bull19: 609–616

    Article  CAS  Google Scholar 

  73. Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings.Schizophr Bull23: 637–651

    Article  PubMed  CAS  Google Scholar 

  74. Waddington JL, Scully PJ, O’Callaghan E (1997) The new antipsychotics, and their potential for early intervention in schizophrenia.Schizophr Res28: 207–222

    Article  PubMed  CAS  Google Scholar 

  75. Gerlach J, Casey DE (1994) Drug treatment of schizophrenia: myths and realities.Curr Opinion Psychiat7: 65–70

    Article  Google Scholar 

  76. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis.Psychopharmacology124: 2–34

    Article  PubMed  CAS  Google Scholar 

  77. Kerwin R, Taylor D (1996) New antipsychotics: a review of their current status and clinical potential.CNS Drugs6: 71–82

    Article  CAS  Google Scholar 

  78. Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, Varghese F, George T, Hustig H, Burnett P et al (1994) The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia.Acta Psychiat Scand90: 358–365

    Article  PubMed  CAS  Google Scholar 

  79. Copolov D (1997) New name for atypical antipsychotics? Am J Psychiat 154: 439

    PubMed  CAS  Google Scholar 

  80. Kane JM (1997) Commentary on “What makes an antipsychotic atypical?”CNS Drugs7: 347–348

    Article  CAS  Google Scholar 

  81. Davis JM (1976) Comparative doses and costs of antipsychotic medication.Arch Gen Psychiat33: 858–861

    Article  PubMed  CAS  Google Scholar 

  82. Bosanquet N (1995) Schizophrenia: developing new strategies for effective care.Br JMed Econ8: 51–64

    Google Scholar 

  83. Knapp M (1997) Costs of schizophrenia.Br JPsychiat171: 509–518

    Article  CAS  Google Scholar 

  84. Robert G, Kennedy P (1997) Establishing cost-effectiveness of atypical neuroleptics.BrJPsychiat171: 103–104

    CAS  Google Scholar 

  85. Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia.Schizophr Bull17: 325–351

    Article  PubMed  CAS  Google Scholar 

  86. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR (1992) Duration of psychosis and outcome in first-episode schizophrenia.Am J Psychiat149: 1183–1188

    PubMed  CAS  Google Scholar 

  87. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE (1996) Course of treatment response in first-episode and chronic schizophrenia.Am JPsychiat153: 519–525

    CAS  Google Scholar 

  88. Scully PJ, Coakley G, Kinsella A, Waddington JL (1997) Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated vs. subsequently treated psychosis in chronic schizophrenia.Psychol Med27: 1303–1310

    Article  PubMed  CAS  Google Scholar 

  89. Wyatt RJ, Green MF, Tuma AH (1997) Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data.Psychol Med27: 261–268

    Article  PubMed  CAS  Google Scholar 

  90. Meagher D, Quinn J, Murphy P, Kinsella A, Mullaney J, Waddington JL (1998) Duration of initially untreated psychosis predicts selectively the “psychomotor poverty” factor in schizophrenia.Schizophr Res29: 37

    Article  Google Scholar 

  91. Waddington JL, Scully PJ (1998) Untreated psychosis and long-term outcome in schizophrenia.Schizophr Bull24: 34–35

    Article  PubMed  CAS  Google Scholar 

  92. McGlashan TH, Johannessen JO (1996) Early detection and intervention with schizophrenia: rationale.Schizophr Bull22: 201–222

    Article  PubMed  CAS  Google Scholar 

  93. Birchwood M, McGorry P, Jackson H (1997) Early intervention in schizophrenia.Br J Psychiat170: 2–5

    Article  CAS  Google Scholar 

  94. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ (1996) EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 22: 305–326

    Article  PubMed  CAS  Google Scholar 

  95. Sheitman BB, Lee H, Strauss R, Lieberman JA (1997) The evaluation and treatment of first-episode psychosis.Schizophr Bull23: 653 —661

    Article  PubMed  CAS  Google Scholar 

  96. Lehman AF, Steinwachs DM, and the co-Investigators of the PORT project (1998) At issue: translating research into practice: The schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.Schizophr Bull24: 1–10

    Article  PubMed  CAS  Google Scholar 

  97. Lehman AF, Steinwachs DM and the survey co-Investigators of the PORT project (1998) Patterns of usual care for schizophrenia: initial results from the schizophrenia Patient Outcomes Research Team (PORT) client survey.Schizophr Bull24: 11–20

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, St. Stephen’s Green, Dublin 2, Ireland

    John L. Waddington & John F. Quinn

  2. Stanley Foundation Research Unit, St. Davnet’s Hospital, Monaghan, Ireland

    John L. Waddington & John F. Quinn

Authors
  1. John L. Waddington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John F. Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Psychoneuropharmacology, University of Nijmegen, Nijmegen, P.O. Box 9101, NL-6500, The Netherlands

    Bart A. Ellenbroek  & Alexander R. Cools  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Waddington, J.L., Quinn, J.F. (2000). From first to second generation antipsychotics. In: Ellenbroek, B.A., Cools, A.R. (eds) Atypical Antipsychotics. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8448-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8448-8_2

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9571-2

  • Online ISBN: 978-3-0348-8448-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation